FDA Panel Backs Traditional Approval of Lecanemab for Alzheimer Disease

An FDA committee voted unanimously that lecanemab-irmb (Leqembi) shows clinical benefit for the treatment of Alzheimer disease.

Related Keywords

, Drug Administration , Central Nervous System Drugs Advisory Committee , Priority Review , Biologics License Application , Clinical Dementia Rating Sum , Scale Cognitive Subscale ,